Evidence Based Medicine

152 articles
by Anne Fortier E. Richard Gold

Beating antibiotic resistance takes new policies, not just new drugs

As we mark World Antimicrobial Resistance (AMR) Awareness Week Nov. 18-24, the message is a familiar one: drug-resistant infections are rising, our antibiotics are losing their power, and we need new ones.

by Tania Kazi Shaurya Taran

Surviving isn’t enough: The unfinished work of post-ICU care

For decades, survival has been one of the clearest measures of success in critical care. A patient arrives in the intensive care unit (ICU) critically ill, survives and eventually leaves the hospital. From the outside, it can look like a success story. But what happens after they go home?

by Andrew D. Brown

The treatable cause of chronic pelvic pain that Canadian medicine keeps missing

The story I hear in my clinic doesn’t change much. A woman in her 30s or 40s has lived with pelvic pain for years. A dull ache, worse by evening, worse after standing all day at work, sometimes worse after intercourse. She has seen her family doctor, a gynecologist, sometimes two. She has had ultrasounds read as normal, often a laparoscopy that found nothing. Somewhere along the way, someone suggested the pain might be stress or “all in her head.”

by Emily Zhang

PMOS and early adversity: Why schools belong in the health conversation

Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome, affects millions of women worldwide and is one of the most common endocrine disorders among young women. Its roots, however, may begin far earlier than most people realize.

by Tara Moroz

Canada regulates health-product claims. But what does ‘science-backed’ actually mean?

“Science-backed.” “Clinically proven.” “Clinically studied.” I see phrases like these constantly in advertising for supplements and other consumer health products. They are meant to sound reassuring because they seem to answer an important question before we even ask it: Does this product actually work?

by Raphael Hofstein Susan Marlin

Canada can win the race for clinical trials – if we keep up our momentum

A recent Healthy Debate article sounded an important alarm about the state of Canada’s clinical trials competitiveness and highlighted key barriers holding us back in the global race for industry investment. As someone who has spent much of my career working to strengthen Canada’s life sciences and innovation sector, I am deeply troubled by the data shared in that article signaling a decline in industry investment in clinical trials in Canada. But I am equally encouraged by the progress now underway, and by what it tells us about Canada’s ability to compete.

by Shawn Fisk AnneMarie Churchill

Substance use health: A different starting point

For decades, Canada gradually shifted its thinking, and its language, from mental illness to mental health. That evolution was about much more than terminology. It broadened the conversation beyond diagnosis and treatment to include prevention, wellbeing, resilience and the conditions that help people thrive.

by Elyse Lackie

We know how to prevent one of the deadliest cancers affecting women. Why aren’t we doing more of it?

When it comes to cancer prevention, we often imagine breakthrough drugs, expensive technology or years of scientific discovery. But one of the most promising ways to prevent ovarian cancer is already here. It's simple, safe, takes just a few extra minutes in the operating room, and has the potential to save thousands of lives. So why aren't we doing more of it?

by Dr. Vivien Brown

RSV protection has changed. Our conversations need to change, too

Few things are more frightening for a parent than watching a baby struggle to breathe. A child who seemed well suddenly has difficulty feeding, becomes exhausted or needs hospital care. For families, respiratory syncytial virus, or RSV, can mean anxious hours in an emergency department and days at a hospital bedside.

by Dr. Bettina Hamelin Michelle McLean

Canada is losing the race for clinical trials – and patients are paying the price

Canada has long punched above its weight in clinical trial activity: the rigorous, multi-stage research studies that give Canadians early access to breakthrough treatments. For years, we’ve led the G7 in clinical trials per capita – a point of national pride – but that advantage is slipping away, and fast.

by Tania Kazi Ilun Yang

Could we vaccinate against colorectal cancer? Lynch Syndrome may show us how

Imagine being told that you carry a genetic mutation that significantly increases your risk of developing cancer. For many people with Lynch syndrome, that is their reality. They may spend decades undergoing regular colonoscopies and other forms of surveillance, knowing that cancer could still develop. But what if a vaccine could change that?

by Tara Moroz

Most wellness trends aren’t wrong. They’re just not always worth it

A new health trend rarely arrives quietly. It usually comes with a promise: better sleep, more energy, less inflammation, sharper focus, improved metabolism or a more “optimized” life. It sounds scientific. It feels personal. It may come with a wearable score, a testimonial, a supplement, a tracking app or one simple rule that seems easy to follow.

by Kim Hanson

Canada must reclaim its reputation as a leader in diabetes innovation

Despite a history steeped in diabetes-related breakthroughs (the discovery of insulin and a track record of performing more insulin-producing cell transplants than any other country), Canada is at risk of losing ground to global peers who are rapidly advancing clinical trials and commercialization at the national level.

by Sumeet Talwar

Overcoming the insulin taboo

The insulin pen had been sitting on his kitchen table for months. The 46‑year‑old man, a retired Sri Lanka born chef living in the Toronto area, had survived oral cancer, pancreatitis and a lifetime of hard work. But nothing frightened him more than the small plastic pen meant to save his life. On a June morning, during a routine check after his jaw surgery, he finally confessed his fears.

by Mubariz Maqsood

When health advice becomes political identity

For years, we talked about health misinformation as if it were mainly a knowledge problem: patients encountering false claims online, doctors correcting them and the better information winning.

by Tess Lanzarotta

Canada must take the lead on hepatitis C vaccine research

Hepatitis C kills hundreds of thousands of people worldwide each year; in Canada it results in more lost years of life than any other infectious disease. An effective treatment exists, but it is unavailable to many because of cost and other access obstacles. And there is no vaccine. Canada has the researchers, the policy framework and the capacity to help change that.

by Maddie O’Connor

Lifestyle medicine vs. wellness culture: Evidence-based preventative care should not be a luxury product

Evidence-based preventative care should not become a luxury product or a marketplace trend. It should remain a core part of accessible public health care.

by Jan Pezarro Christian Finley

Shamed to death: How stigma, not science, is killing Canadians with lung cancer

Lung cancer screening should be available to everyone at risk, regardless of where they live or the source of their illness. 

by Evan Weber

It’s time to act: Canada needs standardized genetic testing for breast cancer care

Every patient deserves to know if their breast cancer is hereditary, if their treatment could be more precise and if their loved ones are at risk.

by Janice E. Parente

Is industry shaping Canada’s research ethics ecosystem?

Canada’s research governance framework must be strong enough to ensure that research ethics oversight remains independent – and that protecting research participants is its first obligation.

1 of 8